siplizumab


Also found in: Wikipedia.

siplizumab

A humanised anti-CD2 monoclonal antibody for treating transplant rejection, GVHD, autoimmune disorders (e.g., psoriasis, rheumatoid arthritis), inflammatory bowel disease and CD2-positive lymphoproliferative disorders.
References in periodicals archive ?
According to the company, the funds will be used to develop Siplizumab in its lead indication of induction of tolerance in organ transplantation, where it has been successfully used in a phase II trial to permit organ transplants without the need of lifelong immunosuppression as well as to continue to optimise its research efforts led by world-class researchers and clinicians to develop groundbreaking treatments for transplant patients.
Siplizumab (Medi-507) is a humanisedmonoclonal antibody directed against CD2.
In 2003, the company filed INDs for Numax(TM), a potential next-generation antibody targeting respiratory syncytial virus; an anti-IL-9 antibody targeting asthma; and siplizumab, an antibody targeting CD2 for T-cell lymphoma.
This patent rights agreement follows licenses granted to MedImmune in 1997 under Protein Design's antibody humanization patents for Synagis (palivizumab), the first monoclonal antibody approved to prevent an infectious disease, and for siplizumab, an antibody currently in Phase II testing as a treatment for psoriasis.
- Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.